BridgeBio Pharma BBIO Operating Income
Operating Income at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's operating income?
- BridgeBio Pharma (BBIO) reported operating income of -$105.96M in Q1 2026.
- How has BridgeBio Pharma's operating income changed year-over-year?
- BridgeBio Pharma's operating income decreased by 1.5% year-over-year, from -$104.37M to -$105.96M.
- What is the long-term trend for BridgeBio Pharma's operating income?
- Over 4 years (2021 to 2025), BridgeBio Pharma's operating income has grown at a -2.4% compound annual growth rate (CAGR), from -$576.63M to -$523.41M.
- What does operating income mean?
- The profit or loss from core business operations before interest and taxes.
- How do you interpret operating income?
- A move toward positive values indicates progress toward commercial viability and operational self-sufficiency.
- How does operating income compare across companies?
- Commonly negative for pre-commercial biotech companies; positive for mature pharmaceutical companies.